ArticleBMJ public health2026

Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.

Xin Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.